Zhong Guo Jing Ji Wang·2025-11-05 09:10Group 1 - The core point of the news is that Chengda Pharmaceutical (301201.SZ) has seen a significant decline in its stock price, closing at 31.10 yuan with a drop of 6.13% [1] - Chengda Pharmaceutical was listed on the Shenzhen Stock Exchange's ChiNext on January 20, 2022, with an initial public offering (IPO) of 24,174,035 shares at a price of 72.69 yuan per share [1] - The stock reached its highest point at 188.00 yuan on the first day of trading but is currently in a state of decline [1] Group 2 - The total amount raised from the IPO was 1,757.21 million yuan, with a net amount of 1,621.45 million yuan after deducting issuance costs [1] - The actual net fundraising amount exceeded the originally planned amount by 1,108.17 million yuan, which was initially set at 513.28 million yuan for various projects [1] - The total issuance costs for the IPO were 135.76 million yuan, including underwriting fees of 117.93 million yuan [1] Group 3 - On July 3, 2023, Chengda Pharmaceutical announced its 2022 annual equity distribution plan, which includes a cash dividend of 3.00 yuan for every 10 shares and a capital reserve conversion of 6 additional shares for every 10 shares held [2] - The record date for the equity distribution was set for July 6, 2023, with the ex-dividend date on July 7, 2023 [2]